- Inhibitory Selectivity
|Catalog No.||Product Name||Solubility(25°C)|
|S1472||Safinamide Mesylate||80 mg/mL||80 mg/mL||13 mg/mL|
|S2102||Rasagiline Mesylate||53 mg/mL||53 mg/mL||53 mg/mL|
|S4246||Tranylcypromine (2-PCPA) HCl||33 mg/mL||33 mg/mL||33 mg/mL|
|S3212||Moclobemide (Ro 111163)||<1 mg/mL||53 mg/mL||10 mg/mL|
|S3868||Harmine||-1 mg/mL||42 mg/mL||-1 mg/mL|
|S3740||Selegiline HCl||44 mg/mL||<1 mg/mL||<1 mg/mL|
|S3690||Pargyline hydrochloride||39 mg/mL||39 mg/mL||39 mg/mL|
|S4033||Sennoside A||<1 mg/mL||100 mg/mL||<1 mg/mL|
|S2302||Glycyrrhizin (Glycyrrhizic Acid)||<1 mg/mL||100 mg/mL||100 mg/mL|
|S2339||Paeonol||<1 mg/mL||33 mg/mL||33 mg/mL|
|S4717||Isatin||<1 mg/mL||29 mg/mL||10 mg/mL|
- MAO Inhibitors (12)
- New MAO Products
|Catalog No.||Information||Product Use Citations||Product Validations|
Safinamide Mesylate is mesylate salt of Safinamide, selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits 5918-fold selectivity against MAO-A. Phase 3.
Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.
Tranylcypromine is a monoamine oxidase inhibitor, which inhibits CYP2A6 with Ki of 0.08 μM and 0.2 μM in cDNA-expressing microsomes and Human Liver Microsomes, respectively.
Moclobemide is a MAO-A (5-HT) inhibitor with IC50 of 6.1 μM.
Inguinal adipose stromal cells were differentiated into adipocytes, treated with various chemical inhibitors (1 μM) with or without harmine (1 μM) for 24 h, and then harvested for qPCR and western blot analysis (n = 6 wells/group). Quantitative PCR analysis of Ucp1 expression in the adipocytes treated with harmine and (a) DYRK1A inhibitor, (b) MAO-A inhibitor. Data represent mean ± SEM. *p < 0.05.
Iproniazid is a non-selective, irreversible monoamine oxidase (MAO) inhibitor (MAOI) that is used as an antidepressive agent.
Harmine is an alkaloid of the β-carboline family that regulates PPARγ expression through inhibition of the Wnt signaling pathway. It also selectively binds to MAO-A and reversibly inhibits monoamine oxidase A (MAO-A) but not the variant MAO-B.
Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) with selectivity for MAO-B vs MAO-A and used in the treatment of Parkinson's disease.
Pargyline is an irreversible inhibitor of monoamine oxidase (MAO)-B with Ki values of 13 and 0.5 μM for time-dependent inhibition of the activity of MAO-A and -B, respectivey.
Sennoside A, a kind of irritant laxative isolated from rhei rhizome, causes purgative actions in the intestine.
Glycyrrhizin (Glycyrrhizic Acid) is a direct HMGB1(high mobility group box 1) inhibitor that inhibits HMGB1-dependent inflammatory molecule expression and oxidative stress; modulates P38 and P-JNK but not p-ERK signalling; Also inhibits 11 beta-hydroxysteroid dehydrogenase and monoamine oxidase (MAO).
Western blot analysis of TLR2 and CXCR4 after direct inhibition with glycyrrhizin.
Paeonol (Peonol), a phenolic compound extracted from Chinese herbs Paeonia suffruticosa (moutan cortex) and Cynanchum paniculatum, inhibits MAO with an IC50 of about 50 μM.
Isatin is an endogenous MAO inhibitor and more active against MAO-B than MAO-A